Clinical effectiveness and safety of ticagrelor in patients after PCI because of acute non ST segment elevation myocardial infarction

Abstract

Objective: To observe the clinical effectiveness and safety of ticagrelor in patients after percutaneous coronary intervention (PCI) because of acute non ST segment elevation myocardial infarction (NSTEMI) in China. Methods: A total of 240 patients with NSTEMI were analyzed retrospectively from Beijing Anzhen hospital between Jan 2013 and Jan 2015, with 113 patients in the clopidogrel group, 127 in the ticagrelor group. ADP-induced platelet aggregation was investigated 1, 3 and 6 month later after PCI, and major adverse cardiac events (MACE) and thrombolysis in myocardial infarction (TIMI) bleeding were followed-up for 6 months. Results: ADP-induced platelet aggregations of the ticagrelor group [(29±5)%, (29±6)%, (26±7)%] were decreased significantly compared with the clopidogrel group [(50±9)%, (49±9)%, (46±8)%] 1, 3 and 6 month later after PCI (P<0.01). Compared with the clopidogrel group (17.7%), the incidence of MACE of ticagrelor group (7.09%) was significantly decreased 6 month later after PCI (P<0.05), but there were no statistical differences in the incidence of TIMI major bleeding and secondary hemorrhage between the two groups (P>0.05). Conclusion: Ticagrelor combined with aspirin can decrease the MACE incidence of NSTEMI, and do not increase TIMI major bleeding and secondary hemorrhage.